EUVIMEDObjevte EUVIMED
EUVIMED · CrossrefJournal

Cancer Research Communications

ISSN 2767-9764 · American Association for Cancer Research (AACR)

Latest articles

  1. Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation

    Rebecca J. Leeman-Neill, Leonardo P.A. Biral, Devang Thakkar, Chee Leong. Cheng, Shin Yeu. Ong, Sarah L. Ondrejka, Eric Hsi, Jean L. Koff, David L. Jaye, Matthew S. McKinney, Chad M. McCall, Cassandra Love, Jennifer R. Shingleton, Dennis Owusu, Tushar H. Dave, Ayush Batra, Elizabeth Thacker, Clay Parker, Lanie Happ, Amy Chadburn, Mateo Mejia. Saldarriaga, Mary Ann Thompson Arildsen, Ridas Juskevicius, Shaoying Li, Amir Behdad, Carlos Galvez, Abner Louissaint, Dennis P. O'Malley, Andrew Evans, Dina Sameh. Soliman, Rashmi S. Goswami, Jiong Yan, Kikkeri N. Naresh, Sandeep S. Dave, Govind Bhagat

    Published: 2026-11-11DOI: 10.1158/2767-9764.crc-26-0077

  2. Distinguishing Features of Radiation-Induced from Sporadic Thyroid Cancers after the Chornobyl Nuclear Power Plant Accident

    Danielle M. Karyadi, Tetiana I. Bogdanova, Stephen W. Hartley, Vladimir V. Drozdovitch, Sergii Masiuk, Sara J. Schonfeld, Belynda D. Hicks, Kristine Jones, Amy A. Hutchinson, Petra Lenz, Maria Brown, Aaron M. Rozeboom, Elizabeth K. Cahoon, Mykola Chepurny, Liudmyla Yu. Zurnadzhy, Vibha Vij, Cari M. Kitahara, Michael Dean, Gayle E. Woloschak, Dale A. Ramsden, Mykola D. Tronko, Stephen J. Chanock, Lindsay M. Morton

    Published: 2026-11-05DOI: 10.1158/2767-9764.crc-26-0457

  3. Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma

    Suresh Kumar, Yoo Sun Kim, Nai-Yun Sun, George I. Karadimov, Liang Liu, Afeez Ishola, Yasuhiro Arakawa, Briana N. Cortez, Diana Varghese, Arnulfo Mendoza, Katja Kiseljak-Vassiliades, Margaret E. Wierman, Jonathan M. Hernandez, Chuong D. Hoang, Xiaoling Luo, Ross Lake, Stephen M. Hewitt, Mirit I. Aladjem, Yves Pommier, Xiaohu Zhang, Crystal McKnight, Anthony Garrison, Savannah Wood, David Holland, Craig J. Thomas, Jaydira Del Rivero, Nitin Roper

    Published: 2026-11-05DOI: 10.1158/2767-9764.crc-26-0581

  4. A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors

    Thejus Jayakrishnan, Rebecca Porter, Alice Chen, Ningxuan Zhou, Julianne L. Holleran, Massimiliano Russo, Douglas A. Rubinson, Brandon M. Huffman, Nabihah Tayob, Lorenzo Trippa, Kaitlyn Ramsey, Mckenzie Kelly, Leah H. Biller, Panagiotis A. Konstantinopoulos, Carolyn Krassner, Elizabeth K. Lee, Ursula A. Matulonis, Kimberly J. Perez, Renata R. Almeida, Srivatsan Raghavan, Alexi A. Wright, Brian M. Wolpin, Jonathan A. Nowak, Alan D. D'Andrea, Andrew J. Aguirre, Steven Gore, Geoffrey I. Shapiro, Jan H. Beumer, James M. Cleary

    Published: 2026-11-03DOI: 10.1158/2767-9764.crc-26-0505

  5. Comparative Analysis of Ovarian Cancer Tumor-Infiltrating T Cells with Those in Melanoma and before and after PD-1 Blockade

    Ilaria Colombo, Ksenia Meteleva, Simone C. Stone, Anjelica Hodgson, Nicolas Jacquelot, Aras Toker, Azin Sayad, Jehan Vakharia, Valentin Sotov, Christine Tran, Hal K. Berman, Stephenie Prokopec, Giselle Boukhaled, Lisa Wang, Pamela Soberanis Pina, Neesha Dhani, Amit M. Oza, Marcus O. Butler, Lillian L. Siu, Ben X. Wang, Pamela S. Ohashi, Stephanie Lheureux

    Published: 2026-11-01DOI: 10.1158/2767-9764.crc-26-0011

  6. Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer

    Vincenzo Nasca, Gabriele Tinè, Henry Walch, Giulia Maddalena, Marco Maria Germani, Filippo Ghelardi, Eleonora Perissinotto, Chiara Boccaccio, Paolo Manca, Matteo Fassan, Matteo Landi, Camilla Damonte, Eleonora Gusmaroli, Alessia Garavaglia, Francesca Bergamo, Chiara Cremolini, Sara Lonardi, Rosalba Miceli, Filippo Pietrantonio, Giovanni Randon

    Published: 2026-11-01DOI: 10.1158/2767-9764.crc-26-0372

  7. Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial

    Irene M. Briata, Alessio Carbone, Sebastian Foersch, Katrin E. Tagscherer, Wilfried Roth, Dominique Scherer, Tania Buttiron Webber, Matteo Clavarezza, Jürgen Burhenne, Martino Oliva, Mauro D’Amico, Giorgia Giancarli, Massimo Oppezzi, Paola Romagnoli, Mauro Dalla Libera, Borut Stabuc, Thomas Bachleitner-Hofmann, Marilena Petrera, Laura Paleari, Matteo Puntoni, Cornelia M. Ulrich, Andrea DeCensi

    Published: 2026-11-01DOI: 10.1158/2767-9764.crc-26-0556

  8. Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses

    Elia Segui, Jorge Gomez Tejeda Zañudo, Noah Graham, Patrick T. Kurnia, Andrea N. Perry, Nabihah Tayob, Heather A. Parsons, Raechel Davis, Molly K. DiLullo, Jennifer A. Ligibel, Filipa Lynce, Jing Ni, Sara M. Tolaney, Eric P. Winer, Adrienne G. Waks, Jean Zhao, Rinath M. Jeselsohn, Nancy U. Lin, José P. Leone

    Published: 2026-11-01DOI: 10.1158/2767-9764.crc-26-0571

  9. Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative

    Sheren Younes, Fadzai Chinyengetere, Veronica Russell, Devang Thakkar, Emily F. Mason, Ridas Juskevicius, Alexandra E. Kovach, Shaoying Li, C. Cameron Yin, Dennis P. O’Malley, Jean L. Koff, David L. Jaye, Cassandra Love, Jennifer R. Shingleton, Dennis Owusu, Ayush Batra, Leonardo P.A. Biral, Elizabeth Thacker, Clay Parker, Lanie Happ, Jennifer Chapman Fredricks, Izidore S. Lossos, Sarah L. Ondrejka, Eric Hsi, Eric Tse, Rex K.H. Au-Yeung, Govind Bhagat, Rebecca J. Leeman-Neill, Amy Chadburn, Magdalena Czader, Yuri Fedoriw, Kikkeri N. Naresh, Sandeep S. Dave, Yasodha Natkunam

    Published: 2026-10-01DOI: 10.1158/2767-9764.crc-25-0834

  10. ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity

    Durga Meenakshi Panneerdoss, Khaled Mohamed Nassar, Baskaran Subramani, William Cole Arnold, Sai Pranathi Vedagiri Venkata, Joe Hernandez, Behnam Ebrahimi, Sonal R. Chaudhari, Gaurav Sharma, Tae-Kyung Lee, Scott Elmore, Henry Neal, Uday P. Pratap, Gangadhara R. Sareddy, Edward R. Kost, Jung-Mo Ahn, Ganesh V. Raj, Ratna K. Vadlamudi

    Published: 2026-10-01DOI: 10.1158/2767-9764.crc-26-0421

  11. Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam

    Valentina Spielmann, Jonas Buchloh, Selen Selcen, Carolin Schneider, Shaishavi Jansari, Xin Fang, Ningjun Duan, Engin Demirdizen, Lukas Krauß, Jessica Eggert, Geraldine Siegfried, Sandrine Fedou, Christof Lenz, Lena Wieland, Lena-Christin Conradi, Maximilian Reichert, Volker Ellenrieder, Michael Ghadimi, Marian Grade, Elisabeth Hessmann, Abdel-Majid Khatib, Christian J. Braun, Florian Wegwitz, Dieter Saur, Matthias Wirth, Günter Schneider

    Published: 2026-09-01DOI: 10.1158/2767-9764.crc-25-0670

  12. Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling

    Ryan Robb, Sarah E. Ackermann, Seamus E. Degan, Khalilah E. Taylor, Runying Yang, Alexander Zuniga Marler, Valerie Calvert, Mariaelena Pierobon, Scott Lyons, Natalie Barker-Krantz, Aurora Cabrera, Antje Schaefer, Laura E. Herring, Adrienne D. Cox, Emanuel F. Petricoin, Clint A. Stalnecker, Kirsten L. Bryant

    Published: 2026-07-01DOI: 10.1158/2767-9764.crc-25-0731

  13. Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study

    Rahul Aggarwal, Antoine Italiano, Susan M. Domchek, Oscar Goodman, Sophie Postel-Vinay, Jesus Garcia-Donas, Tanya Dorff, Zachery R. Reichert, Armelle Vinceneux, Neal Shore, Catherine H. Marshall, Joshua Armenia, Graeme Parr, Aleksandra Kmieciak, Natalia Lukashchuk, Olga Murina, Daniel Slade, Neel Shah, Bienvenu Loembé, Emma Dean, Elhan Sanai, Wassim Abida

    Published: 2026-07-01DOI: 10.1158/2767-9764.crc-26-0184

Volumes

2026 · 1562025 · 1912024 · 2522023 · 2202022 · 1402021 · 15

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.